目次

1. Introduction to TROP2 Targeting Therapy Market
1.1 Overview
1.2 TROP2 Targeting Therapeutics Mechanism

2. TROP2 Ideal Clinical Biomarker for Cancer

3. First Approved TROP2 Targeting Antibody - Trodelvy
3.1 Clinical Overview
3.2 Approval, Patent and Exclusivity

4. Trodelvy - Commercial Insight 2020 -2022
4.1 Dosage and Price Analysis
4.2 Sales Analysis

5. Global TROP2 Targeting Therapy Market Analysis
5.1 Current Market Scenario (2020 -2022)
5.2 Future Market Opportunity (2023 -2028)

6. Global TROP2 Targeting Therapy Market Opportunity by Region
6.1 US
6.2 Europe
6.3 Japan
6.4 Australia
6.5 UK
6.6 China

7. TROP2 Targeted Therapy Ongoing Clinical Trials Insight
7.1 By Company
7.2 By Country
7.3 By Patient Segment
7.4 By Phase

8. Global TROP2 Antibody Clinical Pipeline By Company, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-III

9. Marketed TROP2 Antibody Clinical Insight

10. Global TROP2 Targeted Therapy Market Dynamics
10.1 Market Drivers
10.2 Market Challenges

11. Competitive Landscape
11.1 Amunix
11.2 BiOneCure Therapeutics
11.3 Biosion
11.4 Bio-Thera Solutions
11.5 CytomX Therapeutics
11.6 Daiichi Sankyo Company
11.7 Eucure Biopharma
11.8 Gilead Sciences
11.9 Hangzhou DAC Biotech
11.10 Janux Therapeutics
11.11 Klus Pharma
11.12 LegoChem Biosciences
11.13 Molecular Templates
11.14 KAEDI Biotech
11.15 Peak Bio
11.16 Radiopharm Theranostics
11.17 Shanghai Henlius Biotech
11.18 Suzhou GeneQuantum Healthcare
11.19 SystImmune

List of Figures & Tables
Figure 1-1: Evolution of TROP2 Targeting Therapeutics
Figure 1-2: TROP2 Stimulated Effectors, Biomarker and Pathways
Figure 1-3: TROP2 Regulated Oncogenic Cell Signaling Pathways
Figure 1-4: General Mechanism of TROP2 Targeting Therapy
Figure 1-5: Trodelvy - Mechanism of Action
Figure 2-1: Frequency of TROP2 Expression by Cancer Type (%)
Figure 2-2: Role of TROP2 in Cancer
Figure 3-1: Trodelvy - Response Rate in Clinical Study (%)
Figure 3-2: Trodelvy - FDA Approval Year Indication
Figure 3-3: Trodelvy - Patent Expiration Year by Region
Figure 3-4: Trodelvy - Approval Year By Country
Figure 3-5: Trodelvy - FDA Orphan Designation Year by Indication
Figure 4-1: Trodelvy - Average Cost of Single Dose Cycle and Single Treatment Cycle (US$), February’2023
Figure 4-2: Global - Annual Trodelvy Sales (US$ Million), 2020-2022
Figure 4-3: Global - Quarterly Trodelvy Sales (US$ Million), 2022
Figure 4-4: Trodelvy Sales By Region (%), 2022
Figure 4-5: Trodelvy Sales By Region (%), 2021
Figure 4-6: US - Annual Trodelvy Sales (US$ Million), 2019-2022
Figure 4-7: US - Quarterly Trodelvy Sales (US$ Million), 2022
Figure 4-8: EU - Annual Trodelvy Sales (US$ Million), 2021-2022
Figure 4-9: EU - Quarterly Trodelvy Sales (US$ Million), 2022
Figure 4-10: ROW - Quarterly Trodelvy Sales (US$ Million), 2022
Figure 4-11: Global - Quarterly Trodelvy Sales (US$ Million), 2021
Figure 4-12: US - Quarterly Trodelvy Sales (US$ Million), 2021
Figure 4-13: EU - Quarterly Trodelvy Sales (US$ Million), 2021
Figure 5-1: Global - Number of Newly Diagnosed Cancer Cases (Million), 2020, 2025 and 2030
Figure 5-2: Global - Number of Cancer Deaths (Million), 2020, 2025 and 2030
Figure 5-3: Global - TROP2 Antibody Sales (US$ Million), 2020-2022
Figure 5-4: Global - Quarterly TROP2 Antibody Sales (US$ Million), 2022
Figure 5-5: Global - TROP2 Antibody Sales By Region (%), 2022
Figure 5-6: Global - TROP2 Antibody Sales By Region (%), 2021
Figure 5-7: Global - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2023-2028
Figure 5-8: Global - TROP2 Targeting Therapy Market Opportunity By Indication (%), 2028
Figure 6-1: US - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
Figure 6-2: US - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2021- 2028
Figure 6-3: Europe - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
Figure 6-4: Europe - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2022-2028
Figure 6-5: Japan - Number of Newly Diagnosed Cancer Cases (Million), 2020-2026
Figure 6-6: Japan - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2023-2028
Figure 6-7: Australia - TROP2 Targeting Therapy Market Opportunity (US$ Million), 2023 - 2028
Figure 7-1: Global -TROP2 Antibody Clinical Pipeline By Company, 2023 till 2028
Figure 7-2: Global -TROP2 Antibody Clinical Pipeline By Country, 2023 till 2028
Figure 7-3: Global -TROP2 Antibody Clinical Pipeline By Patient Segment, 2023 till 2028
Figure 7-4: Global -TROP2 Antibody Clinical Pipeline By Phase, 2023 till 2028
Figure 7-5: Global - TROP2 Related Clinical Trials by Phase (%), November’2022
Figure 10-1: Global TROP2 Targeting Therapy Market Drivers
Figure 10-2: Challenges for Global TROP2 Targeting Therapy Market